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OBJECTIVES: The introduction of targeted therapies for the treatment of metastatic 
renal cell carcinoma (mRCC) has greatly improved patient prognosis compared with 
interferon-alfa (IFN-A). As these therapies differ in clinical efﬁcacy and costs, eco-
nomic evaluations are needed to help decision makers allocate scarce resources. We 
evaluated the cost effectiveness of sunitinib versus bevacizumab plus IFN-A and tem-
sirolimus in patients with mRCC. METHODS: A cost-effectiveness model applying a 
third-party payer perspective was developed to simulate disease progression and sur-
vival using hazard ratios (HRs) for each treatment against IFN-A. The HRs were taken 
from latest data available for the pivotal phase III sunitinib trial and the phase II and 
III clinical trials of temsirolimus and bevacizumab plus IFN-A. Two comparative 
evaluations were made: (1) sunitinib versus bevacizumab  IFN-A in all patients and 
(2) sunitinib versus temsirolimus in patients with modiﬁed MSKCC poor-risk proﬁle 
only. Swedish clinical experts’ opinions and published data on routine follow-up, 
treatment-related adverse events, disease progression, best supportive care of termi-
nally-ill patients, and costs were used to complement clinical trial-based parameters 
and quality of life measures. Model outcomes included life-years (LY), progression-
free LY (PFLY), and quality adjusted LY (QALY) gained, treatment costs (2008 
Swedish krona [SEK]), and incremental cost-effectiveness ratios. RESULTS: Sunitinib 
was more effective (gains of 0.19 PFLY, 0.23 LY and 0.16 QALY) and less costly 
(SEK 307,879) than bevacizumab plus IFN-A over 10 years for all patients. In poor 
risk patients, sunitinib was more effective (gains of 0.12 PFLY, 0.08 LY and 0.07 
QALY) and more costly (SEK 18,024) than temsirolimus over 10 years. Sunitinib was 
cost-effective versus temsirolimus (SEK 265,044/QALY) compared to a threshold of 
SEK 500,000/QALY (a47,169/QALY). CONCLUSIONS: Sunitinib is a cost-effective 
alternative to bevacizumab plus IFN-A and temsirolimus for the ﬁrst-line treatment of 
mRCC in Sweden.
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FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY 
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OBJECTIVES: This study assessed the cost-effectiveness of Rituximab (R) in combina-
tion with Fludarabine and Cyclophosphamide (FC) as ﬁrst-line treatment for patients 
with Chronic Lymphocytic Leukemia (CLL) versus FC from the French Sickness Fund 
perspective. METHODS: A 3 health state (PFS, Progression and Death) Markov model 
with a 15 year life-time horizon was developed from the phase III CLL-8 trial (Hallek 
et al., 2008) with 2.2 years median follow-up. Utility values originated from a HTA-
study in CLL using the EQ-5D York Tariff. Resource use was estimated through 
published data and expert opinion. The analysis was restricted to direct medical costs 
including bone marrow transplantation and blood transfusions reported in CLL-8. 
The unit costs were obtained from French ofﬁcial sources. Costs were discounted at 
3%. Deterministic and probabilistic sensitivity analyses were performed and 95% 
conﬁdence intervals (CI) reported. RESULTS: Patients treated with FC compared with 
R-FC spent longer in progression (0.23 years (CI 0.05–0.44), the mean cost of sup-
portive care for progression represented the main cost driver. The totals per patient 
mean costs were higher for R-FC compared to FC alone due to the higher drug acquisi-
tion costs. However, this was partially offset by the reduction in the mean cost of 
supportive care for progression. Mean incremental life expectancy for patients treated 
with R-FC compared to FC was 1.21 years (CI 0.75–1.67), and when quality adjusted 
was 1.01 years (CI 0.61–1.44), at a cost of a13,585 and a16,226 per life year and 
quality adjusted life year gained, respectively. Univariate and probabilistic sensitivity 
analyses conﬁrmed the stability of the model and resulted in ICERs consistently below 
commonly cited willingness to pay thresholds. CONCLUSIONS: R-FC is a clinically 
effective in ﬁrst-line treatment of CLL patients as well as an economically optimal 
strategy in the management of CLL in France.
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OBJECTIVES: Compare the epidemiological and economic impact of accrued cross-
protection against oncogenic human papillomavirus (HPV) types beyond 16/18 pro-
vided by the bivalent vaccine (bi-v) vs. additional protection against non-oncogenic 
HPV types 6/11 of the quadrivalent vaccine (quadri-v), in France. METHODS: A 
lifetime Markov model calibrated to the French setting was developed to reﬂect 
the natural history of low- (evolving to genital warts—GWs) and high-risk HPV 
(evolving to cervical cancer—CC) infections, together with screening and vaccination 
effects, for a single age cohort of 370,000 14-year-old girls (70% coverage). Transition 
probabilities, costs and utility were estimated from literature, ofﬁcial tariffs and expert 
opinions. Vaccine efﬁcacy was obtained from recent phase III clinical trials (HPV-008 
for bi-v and FUTURE I-II for quadri-v), for comparable cohorts on pre-sexual debut 
population (infection naïve). Life-long protection was assumed for both vaccines. 
Number of Cervical Intraepithelial Neoplastic lesions (CIN), CC, CC deaths and 
GW, QALY and costs were estimated. Costs and outcomes (discounted at 3% and 
1.5% respectively) were compared from a societal perspective without indirect costs. 
RESULTS: Cross-protection of bi-v vs. quadri-v led to additional 29,587 CIN1, 2,928 
CIN2, 99 CC and 32 deaths prevented, while quadri-v prevented 14,302 GWs. It 
resulted in additional 556 QALY gained for bi-v The remaining CIN, CC and GW 
not prevented by vaccines would cost Ma39 for and Ma37 for At the current public 
prices of a111.82 for bi-v and a123,66 for quadri-v per dose, the vaccination program 
would cost Ma143 and Ma150 and be cost-effective at an estimated ICER/QALY of 
a10,611 and a11,833 respectively vs. the absence of vaccination. CONCLUSIONS: 
Both vaccines have different epidemiological impacts with an increased number of 
cancer cases prevented for bi-v, though in France, the economic impact of HPV mass 
vaccination is similar whatever the vaccine selected.
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OBJECTIVES: The ABCSG-12 trial demonstrated that adding zoledronic acid 4 mg 
IV q 6 months (ZOL) to endocrine therapy with goserelin 3.6 mg sc q 28 days plus 
tamoxifen 20 mg oral qd or anastrozole 1 mg oral qd (ET) in premenopausal women 
with hormone receptor positive (HR) early breast cancer (EBC) improves disease free 
survival versus ET alone. The objective of this study was to estimate the cost-effective-
ness of ZOL in this setting from the Greek health care system perspective. METHODS: 
A Markov model was used to project lifetime outcomes and costs of breast cancer 
care for premenopausal women with HR EBC receiving 3 yrs of ET or 3 yrs of ET 
plus ZOL. Cost-effectiveness was measured as the incremental cost per quality 
adjusted life year (QALY) gained. Probabilities of breast cancer recurrence were based 
on ABCSG-12. Probabilities and costs were from the published literature. Results were 
generated under 2 scenarios: 1) beneﬁts of ZOL persist to the 7 yr maximum follow-up 
in ABCSG-12 (trial beneﬁts) and 2) beneﬁts persist until recurrence or death (lifetime 
beneﬁts). RESULTS: Expected costs of 3 yrs of ZOL (medication and administration) 
were a1802. Under the trial beneﬁts scenario, costs of breast cancer recurrence were 
reduced by a58; ZOL was therefore projected to increase total costs by a1764. Under 
the lifetime beneﬁts scenario, costs of breast cancer recurrence were reduced by a1548; 
total expected lifetime costs were therefore increased by a273. QALYs gained with 
ZOL were 0.43 years under the trial beneﬁts scenario and 1.39 years under the lifetime 
beneﬁts scenario. Cost per QALY gained was a4102 and a196 under the two scenar-
ios, respectively. CONCLUSIONS: Adding ZOL to ET in premenopausal women with 
HR EBC is highly cost-effective from the Greek health care system perspective even 
under conservative assumptions regarding the duration of ZOL beneﬁts.
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OBJECTIVES: Zoledronic acid (ZOL) is efﬁcacious in reducing skeletal-related events 
(SREs) due to bone metastases in RCC patients. However limited information is avail-
able on its cost-effectiveness. This study evaluated the economic impact of ZOL 
therapy for RCC patients in France, Germany, and the UK. METHODS: The source 
for this analysis was a retrospective evaluation of a 9-month trial comparing ZOL vs. 
placebo with concomitant antineoplastic treatment in RCC patients with bone metas-
tases. A model was developed to simulate quality-adjusted life years (QALYs) and 
costs by integrating relevant assumptions and published information pertaining to 
SRE-incidence, costs, and effects on quality-of-life (QoL), mortality, drug and admin-
istration costs. It was assumed that patients experienced a 20 to 80% decrease in QoL 
for a month following an SRE, depending on the SRE type. SRE costs were based on 
diagnosis-related group (DRG) tariffs and the published literature. RESULTS: ZOL-
treated patients (n  27) experienced 1.07 fewer SREs, gained discounted QALYs 
(France and Germany  0.1563; the UK  0.1575), and incurred substantially lower 
discounted SRE-related costs (France  a4196, Germany  a3880, the UK  a3355) 
compared with patients who were on placebo (n  19). Inclusive of the treatment 
costs, ZOL savings per patient by country were as follows: France  a1358, Germany 
 a1223, and the UK  a719. According to probabilistic sensitivity analyses, ZOL 
therapy was predicted to result in cost savings in 67% to 77% of 1000 model simula-
tions, depending on the country. The cost per QALY gained was below the threshold 
of a30,000 in approximately 93% of the cases across all countries. CONCLUSIONS: 
ZOL is a cost-saving therapy for bone health management of advanced RCC patients 
in France, Germany, or the UK. This is because ZOL effectively prevents SREs, 
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improves patient QoL, incurs lower health-related costs, and offers a better economic 
utilization of health care resources relative to placebo.
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Joseph I1, Facon T2, Lewis P3, Deniz HB1, Caro JJ1
1United BioSource Corporation, Lexington, MA, USA, 2Centre Hospitalier Universitaire 
(CHU), Lille, France, 3Celgene GmbH, München, Germany
OBJECTIVES: Thalidomide (Thalidomide Pharmion® brand drug) combined with 
melphalan (M) and prednisone (P; MPT) increases progression-free survival (PFS) and 
overall survival (OS) compared to MP. We estimated life-time health and cost conse-
quences of MPT versus MP in Welsh patients with untreated multiple myeloma. 
METHODS: A Markov model with 4 health states: PFS with adverse event, PFS 
without adverse event, progressed, and dead. Transition probabilities and discontinu-
ation were derived from a clinical trial. Within the trial, subjects remained on treat-
ment for up to 12 6-week cycles or until progression or treatment-limiting toxicity. 
Treatment duration and average dose were modelled to match the trial. Thrombo-     
prophylaxis with MPT was included. Utilities associated with adverse events and          
disease states were obtained from the literature. Disease-management costs reﬂect 
clinical practice in Wales. Costs and outcomes were discounted at 3.5% per annum. 
RESULTS: The model estimated 25 months PFS with MPT versus 12 months with 
MP, with OS of 4.03 for MPT versus 2.88 years with MP; a gain of 0.9 (3.22 vs. 
2.32) QALYs. MPT’s higher lifetime costs (£16,937 vs. £1,524), lead to an ICER of 
£17,002 per QALY gained and £13,346 per life-year gained. Probabilistic sensitivity 
analyses showed that the results remained consistent through changes in model param-
eters as 95% of model replications produced costs between 12,750 and 26,500 per 
QALY gained. CONCLUSIONS: Replacing MP with MPT is a cost-effective strategy, 
which can deliver substantial improvements in PFS and OS in a life-limiting orphan 
disease in Wales.
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OBJECTIVES: The REDUCE trial examined whether chemoprevention with a 5-alpha 
reductase inhibitor, dutasteride, reduced the rate of prostate cancer (PCa) detection 
on biopsy. We examine the cost-effectiveness of using dutasteride compared with usual 
care in preventing PCa in men at increased risk as seen in REDUCE. METHODS: A 
Markov model was developed to compare the costs and outcomes of chemoprevention 
with dutasteride 0.5 mg/day or usual care in men 50–75 years, with serum prostate-
speciﬁc antigen (PSA) of 2.5–10 ng/mL (60 years) or 3.0–10 ng/mL ( 60 years), 
and a single negative, prostate biopsy in prior 6 months. The model simulated the 
REDUCE cohort of men annually through different health states (e.g. healthy male, 
PCa, BPH, PCa recurrence) over ten years. Risk of PCa for usual care and dutasteride 
patients was obtained from REDUCE, where dutasteride showed a reduced risk of 
23% and no signiﬁcant increase in high grade tumors. Additional beneﬁts in terms of 
reduction in benign prostate hyperplasia (BPH) progression (e.g. surgeries, acute 
urinary retention) were considered. Impact of adverse events (e.g., incontinence, erec-
tile dysfunction, ejaculatory dysfunction) were considered. Costs and utilities were 
obtained from the published literature. RESULTS: Dutasteride patients experienced 
fewer PCa’s (334 vs. 410 per 1000 patients) and increased costs ($17,237 vs. $13,800) 
compared with usual care patients. Although life years were not signiﬁcantly impacted, 
dutasteride patients incurred an increase in quality-adjusted life years (QALYs) of 
0.15. Chemoprevention with dutasteride was found to be cost-effective with an incre-
mental cost per QALY of $22,562. Results were robust to changes in parameters. 
CONCLUSIONS: Despite increased costs, due to taking a daily drug for prevention, 
the use of dutasteride is cost-effective in men at increased risk for PCa. Use of dutas-
teride for PCa prevention in the appropriate population could reduce the cost associ-
ated with the treatment of PCa and prevent reductions in quality of life associated 
with PCa treatment.
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OBJECTIVES: New therapies have recently been introduced for the treatment of 
mRCC. The objective of this analysis was to evaluate the cost-effectiveness of two 
such treatments, temisirolimus (TEM) and sunitinib (SUN) for the management of 
poor prognosis mRCC patients in Portugal. METHODS: A Markov model simulating 
disease progression in poor prognosis mRCC was developed to estimate cost-utility 
of TEM vs. SUN over 3-year time horizon. Patients in the model move through pro-
gression free survival (PFS), disease progression, or death. Transitions between health 
states were estimated from Weibull curves ﬁtted to overall survival (OS) and PFS of 
interferon (INF), the common comparator in TEM and SUN trials. Hazard ratios of 
treatment effect of TEM and SUN to INF were then applied. PFS and OS were based 
on poor prognosis patient population for TEM and SUN. On-treatment utility esti-
mates were based on EQ5D data. Local costs of drug, administration and medical 
follow-up were used. Analyses were run considering the uncertainty around PFS and 
OS measures using model generated 95% CI. Probabilistic sensitivity analysis was 
conducted to evaluate impact of assumptions on input parameters. RESULTS: The 
mean estimated total cost and QALYs for TEM was a18,757 (range a11,646 to 
a31,141) and 0.584 yrs. (range 0.388 yrs. to 0.794 yrs.). While for SUN the mean 
estimated total cost and QALYs was a14,323 (range a4,958 to a38,875) and 0.381 yrs. 
(range 0.125 yrs. to 0.831 yrs.). The mean incremental cost per QALY for TEM vs 
SUN was a21,783. Within the ranges of uncertainty, 20% of the time TEM could 
dominate SUN and 76% of the time TEM was more costly and more effective. CON-
CLUSIONS: TEM is projected to be cost effective compared to SUN in management 
of poor prognosis mRCC patients.
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OBJECTIVES: ZOL is efﬁcacious vs. PBO in reducing the risk of skeletal-related 
events (SREs) in lung cancer (LC) patients with bone metastases. Limited information 
exists on its economic impact. This study assessed the cost-effectiveness of ZOL in the 
LC setting in France (FR), Germany (DE), UK (UK), Portugal (PT), and the Nether-
lands (NL). METHODS: Comparisons of direct costs and quality-adjusted life years 
(QALY) between patients on ZOL vs. PBO were assessed using a literature-based 
model. Clinical information on survival, SRE incidence and infusions administered 
were obtained from a randomised clinical trial in LC patients, comparing 4 mg ZOL 
(every 3 weeks for 21 months) to PBO. Drug acquisition and administration costs 
were obtained from publicly available sources. SRE costs were obtained from Diag-
nosis-Related Group (DRG) tariffs and published information in FR, UK, and DE and 
from retrospective medical record reviews in NL and PT. RESULTS: The expected 
average survival for patients on ZOL and placebo was the same (8.5 months [median 
 5.89 months]). Per-patient (pp) SRE occurrence was projected to be higher and 
QALYs lower in PBO group (SREs  2.07; QALYs  0.292) vs. ZOL-treated patients 
(SREs  1.32; QALYs  0.352). ZOL drug-related costs ranged from a1510 in DE 
and a1484 per patient (pp) in UK. The use of ZOL was associated with a reduction 
in SRE costs ranging from a1.15 pp in FR to a1942 pp in NL. Overall, ZOL saved 
a319 pp in NL, followed by a291 in DE, a216 in UK, a67 in PT, and a2 in FR. In 
sensitivity analysis the cost per QALY gained remained under a50,000 in a wide range 
of scenarios. CONCLUSIONS: ZOL leads to fewer SREs and better estimated quality 
of life. This multinational evaluation reports ZOL to be a highly cost-effective treat-
ment relative to PBO for LC patients with bone metastases.
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OBJECTIVES: To develop a cost-effectiveness evaluation of the use of 
capecitabinedocetaxel vs gemcitabinedocetaxel in patients with recurrent breast 
cancer who previously failed to anthracycline chemotherapy and/or with metastatic 
disease. METHODS: A Markov model was built in order to show the clinic course 
of a cohort of patients with recurrent breast cancer who previously failed to anthra-
cycline chemotherapy and/or with metastatic disease in order to set a quantitative 
comparison between the costs associated in the schemes at the institutional Mexican 
context. The model includes three health states (no progression, progression and 
death), within a 12 months horizon. The outcomes obtained as effectiveness measure 
is Progression-Free Survival (PFS); in order to deﬁne resources and procedures to set 
costs a literature search for economic evaluation and different disease management 
alternatives was done; the costs used to run the model included diagnosis, treatment, 
following and medical support. The threshold to deﬁne a therapy as cost-effective was 
ﬁxed at US$25,020.00 (least than three times Mexican GDP per capita) following the 
recommendations of WHO’s Commission on Macroeconomics and Health. RESULTS: 
The total management cost at 12 moths with capecitabinadocetaxel is US$23,117.90 
vs US$23,978.12 for gemcitabinadocetaxel. The Cost-effectiveness plane indicates 
capecitabinadocetaxel is a cost-effective therapy; with a probability of 0.50 of being 
cost saving and 0.80 to be cost-efective is at a US$25,020.00 threshold. CONCLU-
SIONS: Results show that capecitabinedocetaxel is a cost effective therapy when 
comparing with gemcitabinedocetaxel therapy in ﬁrst line therapy for patients with 
breast cancer who previously failed to anthracycline chemotherapy and/or with meta-
static disease.
